

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Technology Appraisal

Alitretinoin for the treatment of chronic eczema of the hand, refractory to steroids

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Ligand Pharmaceuticals (alitretinoin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Against Allergy • Action for Sick Children • Afiya Trust • Age Concern England • Allergy UK • Black Health Agency • British Ethnic Health Awareness Foundation (BEHAF) • Changing Faces • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Help the Aged • Muslim Council of Great Britain • Muslim Health Network • National Eczema Society • Skin Care Campaign • South Asian Health Foundation • Specialised Healthcare Alliance • WellChild <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Services to the Elderly • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Skin Foundation 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Allergan (tarotene) • Astellas (tacrolimus) • Celltech (betnesol) • Crookes (tretinoin) • Galderma (adapalene) • GlaxoSmithKline (azathioprine) • Janssen-Cilag (tretinoin) • Merck Sharp & Dohme (hydrocortisone) • Novartis (ciclosporin, mycophenolate mofetil, bastilyimab, pimecrolimus) • Pharmacia (hydrocortisone, methylprednisolone) • Roche (acitretin, tretinoin, isotretinoin, mycophenolate mofetil, daclizumab) • Serono (efalizumab)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Community Practitioners and Health Visitors Association • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Barnsley PCT • Brent PCT • Department of Health • Welsh Assembly Government 	<ul style="list-style-type: none"> • Shire Pharmaceuticals (deflazacort) • Soverign (hydrocortisone) • Stiefel (isotretinoin) • Wyeth (etanercept, sirolimus) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham • MRC Clinical Trials Unit • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of the Elderly • Skin Research Centre • Skin Treatment & Research Trust • The British Epidermo-Epidemiology Society <p><u>Evidence Review Group/ Assessment group tbc</u></p> <ul style="list-style-type: none"> • Evidence Review Group/ Assessment group tbc • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • GDG/NCC tbc <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.